Please use this identifier to cite or link to this item:
https://doi.org/10.1097/01.tp.0000166921.14670.33
DC Field | Value | |
---|---|---|
dc.title | Randomized trial of alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation | |
dc.contributor.author | Vathsala, A | |
dc.contributor.author | Ona, ET | |
dc.contributor.author | Tan, SY | |
dc.contributor.author | Suresh, S | |
dc.contributor.author | Lou, HX | |
dc.contributor.author | Casasola, CBC | |
dc.contributor.author | Wong, HC | |
dc.contributor.author | Machin, D | |
dc.contributor.author | Chiang, GSC | |
dc.contributor.author | Danguilan, RA | |
dc.contributor.author | Calne, R | |
dc.date.accessioned | 2022-07-29T07:14:09Z | |
dc.date.available | 2022-07-29T07:14:09Z | |
dc.date.issued | 2005-09-27 | |
dc.identifier.citation | Vathsala, A, Ona, ET, Tan, SY, Suresh, S, Lou, HX, Casasola, CBC, Wong, HC, Machin, D, Chiang, GSC, Danguilan, RA, Calne, R (2005-09-27). Randomized trial of alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Transplantation 80 (6) : 765-774. ScholarBank@NUS Repository. https://doi.org/10.1097/01.tp.0000166921.14670.33 | |
dc.identifier.issn | 0041-1337 | |
dc.identifier.issn | 1534-6080 | |
dc.identifier.uri | https://scholarbank.nus.edu.sg/handle/10635/229456 | |
dc.description.abstract | Background. A randomized, multicenter, controlled trial was undertaken to evaluate the safety and efficacy of Alemtuzumab, a powerful lytic agent for both T and B lymphocytes, in the prophylaxis of rejection in renal transplantation (RTx). Methods. Thirty patients were randomized to receive Alemtuzumab together with low-dose cyclosporine (CsA) monotherapy (CAMPATH, n=20) or to full doses of CsA with azathioprine and corticosteroids (Standard, n=10). CsA was administered at doses to achieve whole-blood trough CsA levels of 90 to 110 ng/mL and 180 to 225 ng/mL in CAMPATH and Standard groups, respectively. Results. Per protocol, CsA trough levels were lower in patients assigned to CAMPATH post-RTx (median trough level of 119 vs. 166 ng/mL at 6 months, CAMPATH vs. Standard; 95% confidence interval, -92 to -34). At 6 months post-RTx, serum creatinine, graft and patient survivals, incidence of biopsy proven acute rejection (25% vs. 20%, CAMPATH vs. Standard), overall treatment failure, and severe and moderate infections were comparable. Whereas all patients receiving Standard therapy required maintenance corticosteroids at 6 months, of the 17 of 20 patients with functioning grafts in CAMPATH, 15 (88%, 95% confidence interval, 53%-97%) were steroid free. Conclusion. These results suggest that Alemtuzumab is an effective induction agent that permits low-dose steroid-free immunosuppression in RTx. Copyright © 2005 by Lippincott Williams & Wilkins. | |
dc.publisher | Ovid Technologies (Wolters Kluwer Health) | |
dc.source | Elements | |
dc.subject | Adolescent | |
dc.subject | Adult | |
dc.subject | Aged | |
dc.subject | Alemtuzumab | |
dc.subject | Antibodies, Monoclonal | |
dc.subject | Antibodies, Monoclonal, Humanized | |
dc.subject | Antibodies, Neoplasm | |
dc.subject | Cyclosporine | |
dc.subject | Female | |
dc.subject | Graft Rejection | |
dc.subject | Humans | |
dc.subject | Immunotherapy | |
dc.subject | Kidney | |
dc.subject | Kidney Function Tests | |
dc.subject | Kidney Transplantation | |
dc.subject | Male | |
dc.subject | Middle Aged | |
dc.subject | Time Factors | |
dc.type | Article | |
dc.date.updated | 2022-07-23T14:20:22Z | |
dc.contributor.department | DEPT OF SURGERY | |
dc.contributor.department | MEDICINE | |
dc.description.doi | 10.1097/01.tp.0000166921.14670.33 | |
dc.description.sourcetitle | Transplantation | |
dc.description.volume | 80 | |
dc.description.issue | 6 | |
dc.description.page | 765-774 | |
dc.published.state | Published | |
Appears in Collections: | Staff Publications Elements |
Show simple item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
Randomised Trial of Alemtuzumab - CAMPATH-1H_TRANSPLANTATION.pdf | 1.14 MB | Adobe PDF | CLOSED | Published |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.